NIVEN RALPH 4
4 · Aerovate Therapeutics, Inc. · Filed Jan 24, 2024
Insider Transaction Report
Form 4
NIVEN RALPH
Chief Development Officer
Transactions
- Award
Stock Option (Right to Buy)
2024-01-22+66,586→ 66,586 totalExercise: $20.00Exp: 2034-01-21→ Common Stock (66,586 underlying)
Footnotes (1)
- [F1]This option shall vest and become exercisable in 48 substantially equal monthly installments, with the first installment vesting on February 22, 2024.